Pharmacy Drugs
Recent Posts
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
- PHT Corporation’s Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur’s Phase II Study Of New Clostridium Difficile Vaccine
Random Posts
- Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial
- No New Year's Joy from FDA
- FDA Approves Labeling Change For VYVANSE CII To Efficacy At 13 Hours Postdose In Children With ADHD
- Exelixis And BMS Report Phase 2 Data To Be Presented At ASCO For XL184 In Patients With Previously Treated Glioblastoma Multiforme
- Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
- Cytokinetics Announces The Initiation Of A First-Time-in-Humans, Phase I Clinical Trial Of CK-2017357
- Full Testing Recommended For Medicinal Products Susceptible To 'Dose Dumping'
- Few Pharmacies Can Translate Prescription Labels Into Spanish
- Genta Announces Top-Line Results Of AGENDA Phase 3 Trial Of Genasense(R) In Patients With Advanced Melanoma
- Ian Facer Is New Chairman Of The National Pharmacy Association (NPA), UK
Noven Reports Positive Phase 2 Results For Mesafem™ Non-Hormonal Therapy For Vasomotor Symptoms
Posted by: admin in Pharmacy Drugs on July 23rd, 2009
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced positive top-line results from its Phase 2 clinical study evaluating Mesafem™ (low-dose paroxetine mesylate) for the treatment of vasomotor symptoms (hot flashes) associated with menopause (”VMS”).
This was a multi-center, double-blind, randomized, placebo-controlled Phase 2 efficacy and safety study of Mesafem in the treatment of VMS. The eight-week study, sponsored by Noven, enrolled 102 patients (with 98 patients completing) at ten clinical locations in the U.S. Patients in the active arm of the study received a dose of Mesafem below 10mg once daily. The primary objective of the study was to assess the safety and efficacy of Mesafem for the treatment of VMS. The primary outcome measures were mean changes in frequency and severity of moderate-to-severe hot flashes from baseline to the fourth and eighth weeks of the study.
“Although designed and powered to detect an efficacy signal, we were very pleased to achieve statistical significance in several primary outcome measures, and to identify clear efficacy signals in the others,” said Joel S. Lippman, M.D., Noven’s Vice President - Clinical Development & Chief Medical Officer. “Safety and tolerability of Mesafem were similar to placebo, with no drug-related serious adverse events. In short, Mesafem appears to be efficacious and well-tolerated at the tested dose, and information from this study should permit us to develop and initiate a well-designed and cost-effective Phase 3 clinical program by year-end.”
Peter Brandt, Noven’s President & CEO, said: “Today’s Phase 2 results exceeded all our internal expectations from the standpoints of both efficacy and tolerability. With the data from this study, we plan to expedite Mesafem into Phase 3 development, and to advance our commercialization and partnering strategies, with the goal of making this new non-hormonal treatment option broadly available to women who suffer from VMS, but who are not candidates for, or who have concerns about, hormone therapy.”
Concurrent with this announcement, Noven issued a press release announcing that it had entered into a definitive merger agreement with Hisamitsu Pharmaceutical Co., Inc. That press release is available at http://www.noven.com.
Source
Noven Pharmaceuticals, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.